0001192482-18-000264.txt : 20180606 0001192482-18-000264.hdr.sgml : 20180606 20180606132513 ACCESSION NUMBER: 0001192482-18-000264 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180606 DATE AS OF CHANGE: 20180606 EFFECTIVENESS DATE: 20180606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mirata Pharmaceuticals, LLC CENTRAL INDEX KEY: 0001742436 IRS NUMBER: 824746856 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-313995 FILM NUMBER: 18883492 BUSINESS ADDRESS: STREET 1: 610 W. GERMANTOWN PIKE, SUITE 400 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: 215-767-4184 MAIL ADDRESS: STREET 1: 610 W. GERMANTOWN PIKE, SUITE 400 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 D 1 primary_doc.xml X0708 D LIVE 0001742436 Mirata Pharmaceuticals, LLC 610 W. GERMANTOWN PIKE SUITE 400 PLYMOUTH MEETING PA PENNSYLVANIA 19462 215-767-4184 DELAWARE Alium Therapeutics, LLC None Limited Liability Company true 2016 Matthew Callahan 610 W. Germantown Pike Suite 400 Plymouth Meeting PA PENNSYLVANIA 19462 Executive Officer Director Maurits Geerlings 610 W. Germantown Pike Suite 400 Plymouth Meeting PA PENNSYLVANIA 19462 Director Pharmaceuticals Decline to Disclose 06b false 2018-06-04 false true false 0 6500000 3900001 2599999 $3,00,000.49 was purchased by a non-US investor false 2 0 0 12722 Reimbursement of expenses. false Mirata Pharmaceuticals, LLC /s/ Matthew Callahan Matthew Callahan Chief Executive Officer 2018-06-06